Oxygen Biotherapeutics and Sarasota Medical Products Sign Binding Letter of Intent to Pursue Joint Research and Development in Chronic Ischemic Wound Care
16. Dezember 2010 02:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today...
Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results
09. Dezember 2010 18:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich...
Oxygen Biotherapeutics Awarded $244,479 Grant Under the Patient Protection and Affordable Care Program
02. November 2010 02:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has received nearly $245,000 in a grant under the Patient...
DERMACYTE(R) Skin Care Products Secure Key Listing on DermStore.com, a Leading Dermatologic and Beauty E-tail Web Site
20. Oktober 2010 08:30 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Oct. 20, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced DERMACYTE® skin care products are now available for purchase...
DERMACYTE(R) Skin Care Products Secure Major Listing on BeautyRiche.com, a Leading Dermatologic and Beauty E-Tail Web Site
19. Oktober 2010 08:30 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Oct. 19, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced DERMACYTE® skin care products are now available for purchase...
Oxygen Biotherapeutics Enters Into Purchase Agreement to Sell $5 Million of Unsecured Promissory Notes to Vatea Fund
13. Oktober 2010 10:31 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Oct. 13, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) entered into a Note Purchase Agreement with JP SPC 1 Vatea, Segregated Portfolio...
Oxygen Biotherapeutics to Showcase New DERMACYTE(R) Oxygen-Enriched Lotions at Leading Spa and Resort Conference in New York City
27. September 2010 10:30 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Sept. 27, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) will showcase for the first time its DERMACYTE oxygen-rich skin care products at...
Oxygen Biotherapeutics Receives DSMB Approval to Proceed to the Next Cohort in Its Phase II-B Clinical Trial for Traumatic Brain Injury
23. September 2010 02:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Sept. 23, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) reported today that the Data Safety Monitoring Board overseeing the company's...
U.S. Navy Broadens CRADA With Oxygen Biotherapeutics to Include Preclinical Studies Assessing Oxycyte(R) for Spinal Cord Injury Due to Decompression Sickness and for Hemorrhagic Shock
20. September 2010 02:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Sept. 20, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced it has amended an existing Cooperative Research and Development...
Oxygen Biotherapeutics Reports First Quarter FY2011 Financial Results
09. September 2010 20:00 ET
|
Oxygen Biotherapeutics, Inc.
DURHAM, N.C., Sept. 9, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT), a development stage biomedical company focused on developing oxygen-rich...